Results 261 to 270 of about 2,472,934 (277)
Some of the next articles are maybe not open access.
Making Risk-Benefit Assessments of Medical Research Protocols
Journal of Law, Medicine & Ethics, 2004Most medical experiments are reviewed by groups known as Institutional Review Boards (IRBs); according to every standard account of medical research ethics, an IRB should not approve an experiment unless it has an acceptable combination of risks and benefits. This requirement is often stated in different terms.
openaire +2 more sources
A Risk-Benefit Assessment of Iron-Chelation Therapy
Drug Safety, 1997Iron overload caused by lifelong transfusion-dependent anaemias, such as beta-thalassaemia major, usually results in lethal cardiac toxicity in the second decade of life if not treated by iron chelation. There is no physiological mechanism for excreting the excess iron accumulated from blood transfusions and, unlike hereditary haemochromatosis ...
openaire +2 more sources
Risk-benefit assessment of angiotensin II receptor antagonists
Expert Opinion on Drug Safety, 2002Inhibiting the renin-angiotensin-aldosterone system through the use of angiotensin-converting enzyme (ACE) inhibitors has proven very useful in the treatment of hypertension, congestive heart failure (CHF) and progressive renal failure. More recently, agents that directly block the angiotensin II Type 1 (AT(1)) receptor--angiotensin II receptor ...
openaire +2 more sources
[Cervical spine manipulation: risks--benefit--assessment].
Revue neurologique, 2004Cervical manipulation is a widely used method indicated in non-specific mechanical neck pain and cervicogenic headache. Cervical manipulation can cause severe neurologic complications which are both rare and generally unpredictable, which can be compared with the accidents occurring with other treatments (nonsteroidal anti-inflammatory drugs...).
Ph, Vautravers, J-Y, Maigne
openaire +1 more source
A Risk-Benefit Assessment of Antileukotrienes in Asthma
Drug Safety, 1998The antileukotriene drugs are the first new therapeutic agents approved for the treatment of asthma in more than 20 years. The currently available compounds are orally active and either prevent the cysteinyl leukotrienes from binding to and activating the cysLT-1 receptor in the lung (leukotriene receptor antagonists) or inhibit leukotriene synthesis ...
openaire +2 more sources
A Risk-Benefit Assessment of Abciximab in Angioplasty
Drug Safety, 1999Advances in percutaneous coronary intervention (PCI) have allowed procedures to be performed on a variety of patients with a spectrum of challenging coronary anatomy. Abciximab has permitted further expansion and has made the procedure safer. Abciximab is a chimerised murine monoclonal antibody directed against the platelet glycoprotein (GP) IIb-IIIa ...
openaire +2 more sources